Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q3 FY21 results · Oct–Dec 2020
Gufic Biosciences reported revenue from operations of ₹144.41 crore (up 47.7% from Q3 FY20) and net profit of ₹13.18 crore (up 87.8% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a standalone basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 144.41 | 97.74 | +47.7% | 120.35 | +20.0% |
| Other income | 0.60 | 3.06 | −80.5% | 2.25 | −73.5% |
| Total income | 145.01 | 100.80 | +43.9% | 122.60 | +18.3% |
| Profit before tax | 18.17 | 9.42 | +92.9% | 22.01 | −17.5% |
| Net profit for the period | 13.18 | 7.02 | +87.8% | 16.33 | −19.3% |
| EPS, basic (₹) | 1.69 | 0.90 | +87.8% | 2.10 | −19.5% |
| Net margin (%) | 9.1 | 7.2 | 13.6 |
Standalone
- Filed with BSE
- 09 Feb 2021, 08:33 IST
- Board meeting
- 08 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE